Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

263.55
-14.4700-5.20%
Volume:675.60K
Turnover:179.09M
Market Cap:7.34B
PE:-20.49
High:273.96
Open:273.74
Low:260.07
Close:278.02
52wk High:392.70
52wk Low:50.56
Shares:27.85M
Float Shares:24.08M
Volume Ratio:1.52
T/O Rate:2.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:5.47
PE(LYR):-19.56

Loading ...

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Movement Alert|Praxis Precision Medicines Falls 5.15% in Regular Trading, FDA Extends Relutrigine Review Period by Three Months

Market Focus
·
Jul 02

Analysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), Aurora Cannabis (ACB)

TIPRANKS
·
Jul 01

Praxis Precision Medicines (PRAX) Receives a Buy from Guggenheim

TIPRANKS
·
Jun 30

Analysts Have Conflicting Sentiments on These Healthcare Companies: Outlook Therapeutics (OTLK), Praxis Precision Medicines (PRAX) and Merck & Company (MRK)

TIPRANKS
·
Jun 30

Praxis Precision Medicines (PRAX) Receives a Buy from TD Cowen

TIPRANKS
·
Jun 30

Stocks to Watch: Aerovironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines

Dow Jones
·
Jun 30

FDA Extends Review Timeline for Praxis’ Relutrigine NDA

TIPRANKS
·
Jun 30

Praxis Precision Medicines Says FDA Extends Review of Relutrigine Application

Dow Jones
·
Jun 30

Praxis Precision Medicines - FDA Extends Review Period for Relutrigine Nda for Scn2a and Scn8a Dees by Three Months

THOMSON REUTERS
·
Jun 30

Praxis Precision Medicines - FDA Sets Updated Pdufa Date of December 27, 2026 for Relutrigine

THOMSON REUTERS
·
Jun 30

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

GlobeNewswire
·
Jun 30

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 29

Praxis Precision Med is Maintained at Buy by Needham

Dow Jones
·
Jun 29

Praxis Precision Medicines Inc : Needham Raises Target Price to $575 from $537

THOMSON REUTERS
·
Jun 29

U.S. Research Roundup-3m Co, Nike, Primoris Services

Reuters
·
Jun 29

Praxis Precision Medicines Director Jill Desimone Disposes of Common Shares Worth $3.23 Million

Reuters
·
Jun 27

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 23

Praxis wins FDA breakthrough therapy tag for elsunersen in SCN2A-DEE seizures

Reuters
·
Jun 22

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated With Scn2a Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

THOMSON REUTERS
·
Jun 22